🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT05893979
Active, not recruiting Not applicable

Myopia Control Spectacle Lens Cessation Study

NCT05893979 · tracked via the Priya Life Science USA tracker
Sponsor
SightGlass Vision, Inc.
Phase
Not applicable
Started
2023-06-23
Last updated
2026-05-05

Condition(s) studied

MyopiaMyopia ProgressionJuvenile Myopia

Investigational drug(s) / intervention(s)

Spectacle Lenses

Spectacle Lenses: Standard Spectacle Lenses

Study summary

To quantify myopic progression (cycloplegic spherical equivalent refraction - cSER) following the cessation of use of specific spectacle lenses.

To quantify axial length progression following cessation of use of specific spectacle lenses.

Eligibility

Sex
ALL
Min age
9 Years
Max age
16 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Previously a successfully completed participant in the CYPRESS Extension study; * Agree to wear the assigned spectacles constantly except for sleeping, swimming, or other activities in which spectacle wear would be dangerous or otherwise not possible (minimum of 10 hours per day); * Willingness to participate in the trial for up to 12 months without contact lens wear; * The subject's parent(s) or legal guardian(s) must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form. Exclusion Criteria: * Known allergy to proparacaine, tetracaine, or tropicamide.

Primary outcome measure(s)

Trial sites (8)

FacilityCityRegionStatus
Golden Optometric Group Whittier California
Omega Vision Center PA Longwood Florida
Kannarr Eye Care Pittsburg Kansas
Advanced Eyecare PC Raytown Missouri
Sacco Eye Group Vestal New York
Total Eye Care Memphis Tennessee
Vision Optique Houston Texas
William J Bogus, OD, FAAO Salt Lake City Utah
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05893979 on ClinicalTrials.gov ↗ ← All trials in the USA